Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 965987, 9 pages
http://dx.doi.org/10.1155/2015/965987
Research Article

An Expedient Synthesis, Acetylcholinesterase Inhibitory Activity, and Molecular Modeling Study of Highly Functionalized Hexahydro-1,6-naphthyridines

1Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
2School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia
3School of Chemical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia
4Pharmacogenetic and Novel Therapeutic Institute for Research in Molecular Medicine, Universiti Sains Malaysia, 11800 Penang, Malaysia

Received 17 November 2014; Revised 9 January 2015; Accepted 9 January 2015

Academic Editor: Miroslav Pohanka

Copyright © 2015 Abdulrahman I. Almansour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Nordberg, “Biological markers and the cholinergic hypothesis in Alzheimer's disease,” Acta Neurologica Scandinavica, vol. 85, no. 139, pp. 54–58, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. A. V. Terry Jr. and J. J. Buccafusco, “The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development,” The Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 821–827, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Prince, R. Bryce, and C. Ferri, World Alzheimer Report 2011: The Benefits of Early Diagnosis and Intervention, Alzheimer's Disease International (ADI), London, UK, 2011.
  4. P. T. Nelson, E. Head, F. A. Schmitt et al., “Alzheimer's disease is not ‘brain aging’: neuropathological, genetic, and epidemiological human studies,” Acta Neuropathologica, vol. 121, no. 5, pp. 571–587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Tabet, “Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!,” Age and Ageing, vol. 35, no. 4, pp. 336–338, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Giacobini, “Cholinesterase inhibitors: new roles and therapeutic alternatives,” Pharmacological Research, vol. 50, no. 4, pp. 433–440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Giacobini, “Invited review. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications,” Neurochemistry International, vol. 32, no. 5-6, pp. 413–419, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Rampa, L. Piazzi, F. Belluti et al., “Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]-amino-alkoxyaryl derivatives,” Journal of Medicinal Chemistry, vol. 44, no. 23, pp. 3810–3820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Morphy and Z. Rankovic, “Designed multiple ligands. An emerging drug discovery paradigm,” Journal of Medicinal Chemistry, vol. 48, no. 21, pp. 6523–6543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cavalli, M. L. Bolognesi, A. Minarini et al., “Multi-target-directed ligands to combat neurodegenerative diseases,” Journal of Medicinal Chemistry, vol. 51, no. 7, pp. 347–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. Larner, “Alzheimer's disease: targets for drug development,” Mini-Reviews in Medicinal Chemistry, vol. 2, no. 1, pp. 1–9, 2002. View at Google Scholar · View at Scopus
  12. J. Y. Melamed, M. S. Egbertson, S. Varga et al., “Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 19, pp. 5307–5310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Egbertson, H. M. Moritz, J. Y. Melamed et al., “A potent and orally active HIV-1 integrase inhibitor,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 5, pp. 1392–1398, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Falardeau, H. Lachance, A. S. Pierre et al., “Design and synthesis of a potent macrocyclic 1,6-napthyridine anti-human cytomegalovirus (HCMV) inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 6, pp. 1693–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Chan, H. Jin, T. Stefanac et al., “Discovery of 1,6-naphthyridines as a novel class of potent and selective human cytomegalovirus inhibitors,” Journal of Medicinal Chemistry, vol. 42, no. 16, pp. 3023–3025, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Thompson, C. J. C. Connolly, J. M. Hamby et al., “3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase,” Journal of Medicinal Chemistry, vol. 43, no. 22, pp. 4200–4211, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Vanlaer, A. Voet, C. Gielens, M. de Maeyer, and F. Compernolle, “Bridged 5,6,7,8-tetrahydro-1,6-naphthyridines, analogues of huperzine A: synthesis, modelling studies and evaluation as inhibitors of acetylcholinesterase,” European Journal of Organic Chemistry, no. 5, pp. 643–654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. N. Jachak, S. M. Bagul, M. A. Kazi, and R. B. Toche, “Novel synthetic protocol toward pyrazolo[3,4-h]-[1,6] naphthyridines via Friedlander condensation of new 4-aminopyrazolo[3,4-b] pyridine-5-carbaldehyde with reactive α-methylene ketones,” Journal of Heterocyclic Chemistry, vol. 48, no. 2, pp. 295–300, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. V. Rote, S. M. Bagul, D. P. Shelar, S. R. Patil, R. B. Toche, and M. N. Jachak, “Synthesis of benzo[3,4-h][1,6]naphthyridines via Friedländer condensation with active methylenes,” Journal of Heterocyclic Chemistry, vol. 48, no. 2, pp. 301–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. R. B. Toche, B. P. Pagar, R. R. Zoman, G. R. Shinde, and M. N. Jachak, “Synthesis of novel benzo[h][1,6]naphthyridine derivatives from 4-aminoquinoline and cyclic β-ketoester,” Tetrahedron, vol. 66, no. 27-28, pp. 5204–5211, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Chandra, B. Singh, S. Upadhyay, and R. M. Singh, “Copper-free Sonogashira coupling of 2-chloroquinolines with phenyl acetylene and quick annulation to benzo[b][1,6] naphthyridine derivatives in aqueous ammonia,” Tetrahedron, vol. 64, no. 51, pp. 11680–11685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Basiri, V. Murugaiyah, H. Osman, R. S. Kumar, Y. Kia, and M. A. Ali, “Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives,” Bioorganic and Medicinal Chemistry, vol. 21, no. 11, pp. 3022–3031, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Kia, H. Osman, R. S. Kumar et al., “A facile chemo-, regio- and stereoselective synthesis and cholinesterase inhibitory activity of spirooxindole-pyrrolizine-piperidine hybrids,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 10, pp. 2979–2983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Basiri, V. Murugaiyah, H. Osman et al., “An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study,” European Journal of Medicinal Chemistry, vol. 67, pp. 221–229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. R. S. Kumar, A. Ramar, S. Perumal, A. I. Almansour, N. Arumugam, and M. A. Ali, “Three-component synthesis and 1,3-dipolar cycloaddition of highly functionalized pyrans with nitrile oxides: easy access to 1,2,4-oxadiazoles,” Synthetic Communications, vol. 43, no. 20, pp. 2763–2772, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. S. Kumar, A. I. Almansour, N. Arumugam et al., “An expedient synthesis and screening for antiacetylcholinesterase activity of piperidine embedded novel pentacyclic cage compounds,” Medicinal Chemistry, vol. 10, no. 2, pp. 228–236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. G. L. Ellman, K. D. Courtney, V. Andres Jr., and R. M. Featherstone, “A new and rapid colorimetric determination of acetylcholinesterase activity,” Biochemical Pharmacology, vol. 7, no. 2, pp. 88–95, 1961. View at Publisher · View at Google Scholar · View at Scopus
  28. J. R. Dimmock, M. P. Padmanilayam, R. N. Puthucode et al., “A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues,” Journal of Medicinal Chemistry, vol. 44, no. 4, pp. 586–593, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Jain, F. Roschangar, and M. A. Ciufolini, “A one-step preparation of functionalized 3-cyano-2-pyridones,” Tetrahedron Letters, vol. 36, no. 19, pp. 3307–3310, 1995. View at Publisher · View at Google Scholar · View at Scopus